Compare Transocean Ltd (RIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Transocean Ltd trades at $5.3 (market cap $5.80B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals.
| RIG | XBI | |
|---|---|---|
Market Cap | $5.80B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $7.58 | $164.28 |
52-Week Low | $2.80 | $85.16 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean Ltd. (RIG) trades at $5.02, down 2.33% today, reflecting ongoing investor caution despite recent contract wins. The stock shows a bearish technical bias with moving averages signaling sell pressure, while fundamentals reveal persistent net losses (-$2.92B in 2025) despite high gross margins (84.88%). Recent news highlights a $1B+ Equinor contract and pending Valaris merger, boosting long-term revenue visibility but failing to offset near-term profitability concerns.
RIG's investment case hinges on backlog execution and merger synergies, offering potential upside to the $7.00 consensus target. However, high leverage, volatile oil prices, and consecutive earnings misses pose significant risks. Analyst sentiment is divided (39% Buy, 39% Hold), suggesting cautious optimism amid operational challenges.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
